Kang Jeehoon, Park Sungjoon, Han Minju, Park Kyung Woo, Han Jung-Kyu, Yang Han-Mo, Kang Hyun-Jae, Koo Bon-Kwon, Kim Hyo-Soo
Department of Internal Medicine, Cardiovascular Center, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea.
Korean Circ J. 2024 Oct;54(10):603-615. doi: 10.4070/kcj.2024.0017. Epub 2024 Jun 4.
The clinical benefits of complete revascularization (CR) in acute myocardial infarction (AMI) patients are unclear. Moreover, the benefit of CR is unknown in AMI with diabetes mellitus (DM) patients. We sought to compare the prognosis of CR and incomplete revascularization (IR) in patients with AMI and multivessel disease, according to the presence of DM.
A total of 2,150 AMI patients with multivessel coronary artery disease were analyzed. CR was defined based on the angiographic image. The primary endpoint of this study was the patient-oriented composite outcome (POCO) defined as a composite of all-cause death, any myocardial infarction, and any revascularization within 3 years.
Overall, 3-year POCO was significantly lower in patients receiving angiographic CR (985 patients, 45.8%) compared with IR (1,165 patients, 54.2%). When divided into subgroups according to the presence of DM, CR reduced 3-year clinical outcomes in the non-DM group but not in the DM group (POCO: 11.7% vs. 23.2%, p<0.001, any revascularization: 7.2% vs. 10.8%, p=0.024 in the non-DM group, POCO: 24.3% vs. 27.8%, p=0.295, any revascularization: 13.3% vs. 11.3%, p=0.448 in the DM group, for CR vs. IR). Multivariate analysis showed that CR significantly reduced 3-year POCO (hazard ratio, 0.52; 95% confidence interval, 0.36-0.75) only in the non-DM group.
In AMI patients with multivessel disease, CR may have less clinical benefit in DM patients than in non-DM patients.
急性心肌梗死(AMI)患者完全血运重建(CR)的临床益处尚不清楚。此外,CR对合并糖尿病(DM)的AMI患者的益处也未知。我们试图根据DM的存在情况,比较CR与不完全血运重建(IR)在多支血管病变的AMI患者中的预后。
共分析了2150例多支冠状动脉病变的AMI患者。CR根据血管造影图像定义。本研究的主要终点是患者导向性复合结局(POCO),定义为全因死亡、任何心肌梗死以及3年内任何血运重建的复合情况。
总体而言,接受血管造影CR的患者(985例,45.8%)3年POCO显著低于接受IR的患者(1165例,54.2%)。根据DM的存在情况分为亚组时,CR降低了非DM组的3年临床结局,但在DM组中未降低(POCO:非DM组为11.7%对23.2%,p<0.001,任何血运重建:7.2%对10.8%,p=0.024;DM组中POCO:24.3%对27.8%,p=0.295,任何血运重建:13.3%对11.3%,p=0.448,CR与IR相比)。多变量分析显示,仅在非DM组中,CR显著降低了3年POCO(风险比,0.52;95%置信区间,0.36 - 0.75)。
在多支血管病变的AMI患者中,CR对DM患者的临床益处可能低于非DM患者。